Klinge, Lars

[["dc.bibliographiccitation.issue","9-10"],["dc.bibliographiccitation.journal","Neuromuscular Disorders"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Zschuentzsch, Jana"],["dc.contributor.author","Makosch, Gregor"],["dc.contributor.author","Klinge, Lars"],["dc.contributor.author","Tiburcy, Malte"],["dc.contributor.author","Brinkmeier, Heinrich"],["dc.contributor.author","Liebetan, D."],["dc.contributor.author","Schmidt, J."],["dc.date.accessioned","2018-11-07T08:51:10Z"],["dc.date.available","2018-11-07T08:51:10Z"],["dc.date.issued","2011"],["dc.format.extent","710"],["dc.identifier.doi","10.1016/j.nmd.2011.06.984"],["dc.identifier.isi","000295955900233"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21866"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.publisher.place","Oxford"],["dc.relation.conference","16th International Congress of the World-Muscle-Society"],["dc.relation.eventlocation","Algarve, PORTUGAL"],["dc.relation.issn","0960-8966"],["dc.title","Human IgG improves the performance of mdx mice in voluntary wheel running"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","351"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Neurochemistry"],["dc.bibliographiccitation.lastpage","362"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","Zschuentzsch, Jana"],["dc.contributor.author","Zhang, Y."],["dc.contributor.author","Klinker, Florian"],["dc.contributor.author","Makosch, Gregor"],["dc.contributor.author","Klinge, Lars"],["dc.contributor.author","Malzahn, Doerthe"],["dc.contributor.author","Brinkmeier, Heinrich"],["dc.contributor.author","Liebetanz, David"],["dc.contributor.author","Schmidt, Jens"],["dc.date.accessioned","2018-11-07T10:21:27Z"],["dc.date.available","2018-11-07T10:21:27Z"],["dc.date.issued","2016"],["dc.description.abstract","Duchenne muscular dystrophy (DMD) is a severe hereditary myopathy. Standard treatment by glucocorticosteroids is limited because of numerous side effects. The aim of this study was to test immunomodulation by human immunoglobulin G (IgG) as treatment in the experimental mouse model (mdx) of DMD. 2g/kg human IgG compared to human albumin was injected intraperitoneally in mdx mice at the age of 3 and 7weeks. Advanced voluntary wheel running parameters were recorded continuously. At the age of 11 weeks, animals were killed so that blood, diaphragm, and lower limb muscles could be removed for quantitative PCR, histological analysis and exvivo muscle contraction tests. IgG compared to albumin significantly improved the voluntary running performance and reduced muscle fatigability in an exvivo muscle contraction test. Upon IgG treatment, serum creatine kinase values were diminished and mRNA expression levels of relevant inflammatory markers were reduced in the diaphragm and limb muscles. Macrophage infiltration and myopathic damage were significantly ameliorated in the quadriceps muscle. Collectively, this study demonstrates that, in the early disease course of mdx mice, human IgG improves the running performance and diminishes myopathic damage and inflammation in the muscle. Therefore, IgG may be a promising approach for treatment of DMD."],["dc.identifier.doi","10.1111/jnc.13269"],["dc.identifier.isi","000367956800015"],["dc.identifier.pmid","26230042"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42093"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1471-4159"],["dc.relation.issn","0022-3042"],["dc.title","Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","177"],["dc.bibliographiccitation.issue","1-2"],["dc.bibliographiccitation.journal","Journal of Neuroimmunology"],["dc.bibliographiccitation.lastpage","178"],["dc.bibliographiccitation.volume","253"],["dc.contributor.author","Zschuentzsch, Jana"],["dc.contributor.author","Weller, Charlotte"],["dc.contributor.author","Zhang, Y."],["dc.contributor.author","Klinker, Florian"],["dc.contributor.author","Makosch, Gregor"],["dc.contributor.author","Klinge, Lars"],["dc.contributor.author","Metselaar, Josbert M."],["dc.contributor.author","Liebetanz, David"],["dc.contributor.author","Brinkmeier, Heinrich"],["dc.contributor.author","Schmidt, Jens"],["dc.date.accessioned","2018-11-07T09:02:18Z"],["dc.date.available","2018-11-07T09:02:18Z"],["dc.date.issued","2012"],["dc.identifier.isi","000312764800478"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24650"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.publisher.place","Amsterdam"],["dc.relation.conference","11th International Congress of Neuroimmunology (ISNI)"],["dc.relation.eventlocation","Boston, MA"],["dc.relation.issn","0165-5728"],["dc.title","Human IgG but not liposomal prednisolone improves the early clinical course of mdx mice as model for Duchenne muscular dystrophy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1067"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Neuroscience Research"],["dc.bibliographiccitation.lastpage","1077"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Weller, Charlotte"],["dc.contributor.author","Zschuentzsch, Jana"],["dc.contributor.author","Makosch, Gregor"],["dc.contributor.author","Metselaar, Josbert M."],["dc.contributor.author","Klinker, Florian"],["dc.contributor.author","Klinge, Lars"],["dc.contributor.author","Liebetanz, David"],["dc.contributor.author","Schmidt, Jens"],["dc.date.accessioned","2018-11-07T09:11:02Z"],["dc.date.available","2018-11-07T09:11:02Z"],["dc.date.issued","2012"],["dc.description.abstract","For Duchenne muscular dystrophy (DMD), a common myopathy that leads to severe disability, no causal therapy is available. Glucocorticosteroids improve patients' muscle strength, but their long-term use is limited by negative side effects. Thus, pharmacological modifications of glucocorticosteroids are required to increase the efficacy by drug targeting. Liposomal encapsulation augments systemic half-life and local tissue concentrations of glucocorticosteroids and, at the same time, reduces systemic side effects. In this study, the efficacy of novel, long-circulating, polyethylene-glycol-coated liposomes encapsulating prednisolone was compared with free prednisolone in the treatment of mdx mice, a well-established animal model for DMD. Using an objective and sensitive computerized 24-hr detection system of voluntary wheel-running in single cages, we demonstrate a significant impairment of the running performance in mdx compared with black/10 control mice aged 36 weeks. Treatment with liposomal or free prednisolone did not improve running performance compared with saline control or empty liposomes. Histopathological parameters, including the rate of internalized nuclei and fiber size variation, and mRNA and protein expression levels of transforming growth factor (TGF)-beta and monocytes chemotactic protein (MCP)-1 also remained unchanged. Bioactivity in skeletal muscle of liposomal and free prednisolone was demonstrated by elevated mRNA expression of muscle ring finger protein 1 (MuRF1), a mediator of muscle atrophy, and its forkhead box transcription factors (Foxo1/3). Our data support the assessment of voluntary running to be a robust and reproducible outcome measure of skeletal muscle performance during the early disease course of mdx mice and suggest that liposomal encapsulation is not superior in treatment efficacy compared with conventional prednisolone. Our study helps to improve the future design of experimental treatment in animal models of neuromuscular diseases. (C) 2012 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/jnr.22825"],["dc.identifier.isi","000301177400015"],["dc.identifier.pmid","22253213"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26632"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","0360-4012"],["dc.title","Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]